Thousands of people in the UK will be screened for hepatitis C virus in a new pilot aimed at expanding use of antiviral therapies to eradicate the infectious – and eliminate it altogether
According to the World Health Organization (WHO), approximately 296 million people globally live with hepatitis B, with most unaware of their infection.
The dramatic improvements in safety, efficacy, tolerability and convenience from the first wave of direct-acting antivirals (DAAs) have made a substantial contribution to changing both the trea
Less than three years after Sovaldi’s launch, hepatitis C (hep C) treatment has been transformed, thanks to the drug and rapidly-evolving competition in the field.
European safety experts are reviewing the latest generation of hepatitis C drugs following cases of re-activation of hepatitis B in patients treated with the medicines, who had been infecte
AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovar
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio